Goldshield Critical Care Europe - a division of Goldshield Pharmaceuticals is one of the largest supplier of small volume parenteral products to UK National Health Service and health sectors within the U.K., Republic of Ireland and other European markets. Antigen Pharmaceuticals, which was acquired by Goldshield Group Plc in November 2001 with a vision to develop niche concept within the secondary care sector is now a part of the Goldshield Critical Care Europe business unit.

Dopram™ (Doxapram) a peripheral respiratory stimulant, Pitressin™ 20IU argipressin presentation, AutoDetect™ a spring loaded loss of resistance syringe for epidural and laparoscopic procedure, Noseeze™ a natural product for management of dryness and crusting of epithelium caused by oxygen therapy, low humidity, air conditioned environments and as a side effect of radiation therapy.

Goldshield Critical Care Europe are the exclusive distributor for United Therapeutics Inc. in UK and Republic of Ireland for a new chemical entity for the management of pulmonary arterial hypertension. This product is already licensed in the USA and in several major European countries.

To further extend and adapt the innovation behind our infusion bag range, we have recently developed a range of combination epidural special infusions which are available upon request. Moreover, we have also developed plastic ampoules to fully complement our existing glass ampoules for most of our popular diluents range and are developing polypropylene ampoules to meet EU environmental guidelines.

The company also promotes several specialised branded pharmaceutical products to the hospital sector such as Robinul™ (glycopyrrolate) a preoperative antimuscarinic drug to reduce secretions